Large-scale clinical trials are needed to verify its efficacy
Many individuals with obesity or type 2 diabetes describe constant internal dialogue about meals, snacks, and portions
This evidence supports current clinical guidelines from the American Diabetes Association and American Heart Association, which recommend long-term or indefinite GLP-1 therapy for eligible patients
Your doctor may also recommend temporarily reducing your Zepbound dose or extending the time between dose increases to allow better tolerance
By understanding your genetic predispositions and baseline metabolic state, you and your provider can make a more confident decision about starting medication, escalation timing, and whether microdose protocols or compounded formulations may enhance tolerability
Always follow your doctors guidance and consult them if symptoms persist